AI for Personalized Medication Management in Parkinson’s Disease
Objective: To assess medication usage over time in Parkinson’s Disease utilizing AI in EHR data. Background: Parkinson's disease (PD) is a complex neurodegenerative disorder characterized…A Comparative Bioavailability Study between a Marketed Capsule-based Levodopa Dry Powder Inhaler and a New Pre-filled Levodopa Dry Powder Inhaler
Objective: The primary objective was to determine the comparative bioavailability between a marketed and a new levodopa dry powder inhaler (DPI) with an enhanced usability…Pregnancy in Parkinson’s disease: Five cases
Objective: To report additional cases to the literature of Parkinson’s disease (PD) and pregnant. Background: Pregnancy in PD is a relatively rare occurrence as PD…Exploring Retrospectively the Predisposing Factors of Sleep Disorders in Parkinson’s Disease.
Objective: Identify the predisposing or exacerbating factors of sleep disorders in Parkinson's disease, and examine their association with levodopa treatment. Background: Parkinson's disease (PD) is…Treatment Patterns With Long-Term Foslevodopa/Foscarbidopa Use in Parkinson’s Disease
Objective: To assess long-term treatment switch patterns and discontinuation rates in patients (pts) with Parkinson’s disease (PD) treated with foslevodopa/foscarbidopa (LDp/CDp) mono- or combination therapy.…Effects of GBA mutations in patients with Parkinson’s disease and Levodopa-carbidopa intestinal gel: a nation-wide longitudinal multicentre ‘real-world’ study.
Objective: To investigate the safety and efficacy of LCIG in PD, focusing on the effects of GBA status. Background: Parkinson's disease carriers of GBA mutations/variants…Cognitive Side Effects to Initial Levodopa Exposure as a “Red Flag”: A Retrospective Study
Objective: To assess if presence of cognitive side effects during an initial levodopa trial suggests the ultimate diagnosis of atypical Parkinson (APD) vs Parkinson disease…A Post Hoc Efficacy Analysis of Phase 3 Trials of Continuous Subcutaneous Foslevodopa/Foscarbidopa in Patients With Parkinson’s Disease
Objective: To further evaluate the efficacy of foslevodopa/foscarbidopa (LDp/CDp), a soluble formulation of levodopa/carbidopa (LD/CD) prodrugs delivered by 24 hour/day customizable continuous subcutaneous infusion, for…Levodopa-Entacapone-Carbidopa Intestinal Gel Treatment In Parkinson’s Disease: A Single-Center Retrospective Chart Study
Objective: The objectives of this chart study were to evaluate adaptations in medication and flow rates and adverse events in patients with Parkinson’s disease (PD)…Association of insomnia with levodopa-related parameters in Parkinson’s disease
Objective: With this analysis we aimed to study the role of insomnia (both sleep onset and sleep maintenance insomnias) in Parkinson’s disease (PD) in relation…
- 1
- 2
- 3
- …
- 57
- Next Page »